Jamjoom Pharma Stock: price and insider trades · Saudi Arabia
Jamjoom Pharma: what insiders have been doing
Jamjoom Pharma has a thin disclosure history in our data (latest filing: 4 July 2023). New filings will appear here as soon as they are published. This summary is built from Tadawul (CMA) disclosures alone and does not predict where the share price will go.
Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Analyst consensus: bullish or bearish?
Analysts rate Jamjoom Pharma Hold (neutral), based on 5 analysts. Average price target: SAR 153.75.
Fundamental score
Ranked 3,642 of 26,897 companies
71.3
score / 100
Value52
Quality91
FCF yld3.8%
Earn yld5.4%
EV/EBITDA16.1x
ROE27%
Gross mgn63%
Net mgn31%
Debt/EBITDA0.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
SAR 123.40
Analyst consensus
5 analystsHold
SAR 144.90Target SAR 153.75(+25%)SAR 160.73
Income statement
RevenueSAR 1.5B
Gross profitSAR 938.8M63% margin
EBITDASAR 537.4M36% margin
Net incomeSAR 463.8M30.5% margin
Valuation
PER (trailing)18.0x
PER (forward)16.0x
P/Book4.6x
Beta0.36
Balance sheet & cash
Market capSAR 8.6B
Total debtSAR 16.4M
Free Cash FlowSAR 332M
Debt / Equity1%
Profitability & ownership
ROE27.0%
ROA14.1%
% insiders61.4%
% institutions3.2%
Last declaration on 4 July 2023
Declarations1 total
- ●Executives0Tadawul
1 of 1 declaration
About Jamjoom Pharma
Jamjoom Pharma is a company focused on health and pharmaceuticals, providing a range of pharmaceutical products. It is listed on the XSAU market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations